ReviewPigment cell & melanoma research2026
CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice.
Review in Pigment cell & melanoma research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is an aggressive skin cancer that, once metastatic, accounts for a disproportionate share of skin-cancer mortality. Contemporary management includes surgical excision with sentinel-node assessment, adjuvant or neoadjuvant systemic therapy, radiotherapy in selected settings, targeted inhibition for BRAF/MEK-mutant disease, and intralesional modalities; nevertheless, many patients require effective systemic options. Immunotherapy has transformed outcomes by restoring antitumor T-cell activity. Within this paradigm, activation of CD40, a pivotal costimulatory receptor on antigen-presenting cells (APCs), has emerged as a means to reprogram tumor immunity in melanoma. Available agents span several classes, including agonist monoclonal antibodies, CD40L-based fusion proteins, and engineered bispecific or conditionally activatable formats. A principal mechanism is dendritic-cell licensing that enhances cross-priming of melanoma-specific CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.